OKYO Pharma Ltd (OKYO) has 14 SEC Form 4 insider filings on record in the last 90 days. That includes 7 insider purchases totalling $136K. Most recent filing: Aug. 7, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 7, 2026 filed July 21, 2026 | JACOB GARY S CHIEF DEVELOPMENT OFFICER | +$4,900 | 3,500 | +3% | No | |
|
|
||||||
| Aug. 7, 2026 filed July 22, 2026 | Dempsey Robert John CHIEF EXECUTIVE OFFICER | +$23,085 | 15,000 | New | No | |
|
|
||||||
| Aug. 7, 2026 filed July 21, 2026 | BRANCACCIO JOHN P Director | +$7,385 | 5,000 | +17% | No | |
|
|
||||||
| Aug. 7, 2026 filed July 27, 2026 | Patil Rajkumar V. Chief Scientific Officer | +$5,011 | 3,363 | +20% | No | |
|
|
||||||
| Aug. 7, 2026 filed July 21, 2026 | CERRONE GABRIELE M Director | +$32,625 | 22,500 | +0% | No | |
|
|
||||||
Showing the 5 most recent of 14 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free